Surmodics (SRDX) Azione Prezzo
Surmodics Prezzo
Negli ultimi 19 anni Surmodics ha aumentato il fatturato del 3,8% all'anno, raggiungendo 126,08 Mio. USD. L'utile per azione è diminuito del 8,2% all'anno negli ultimi 15 anni. Per Surmodics, il margine netto del -9,2% risulta in calo rispetto al 1,2% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Surmodics è 43,86 USD, circa il 2,0% sopra il prezzo attuale di mercato. Su 9 analisti, 6 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Surmodics Prezzo delle azioni
Surmodics Azione e analisi azionaria
Domande frequenti sull'azione Surmodics
Surmodics Inc. is a medical technology company that operates through two segments: Medical Devices and In Vitro Diagnostics. The company's business model revolves around developing and commercializing innovative products and technologies that enhance the diagnosis and treatment of diseases. Surmodics' Medical Devices segment focuses on providing surface modification technologies to medical device manufacturers, enabling them to improve device performance and biocompatibility. On the other hand, the In Vitro Diagnostics segment offers proprietary diagnostic technologies and reagent coatings for various healthcare tests. Through its diversified business model, Surmodics strives to contribute to the advancement of medical care and improve patient outcomes.
Surmodics Inc is primarily active in the healthcare and medical device industry.
The main competitors of Surmodics Inc in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.
Surmodics Inc, founded in 1979, is a leading provider of surface modification and in vitro diagnostic technologies. With its headquarters in Eden Prairie, Minnesota, the company develops and manufactures innovative products that enhance the performance of medical devices, improve drug delivery, and support the diagnosis of various diseases. Surmodics has a rich history of pioneering advancements in healthcare, and its expertise in surface modification has helped it establish collaborations with renowned medical device manufacturers globally. As a trusted name in the industry, Surmodics Inc continues to drive innovation and deliver solutions that positively impact patient outcomes and empower healthcare professionals worldwide.
Surmodics Inc has achieved significant milestones in its history. The company introduced its first medical device coating product, SurfaSeal, in 1985, which marked a breakthrough in the field. In 1998, Surmodics launched its first drug delivery coating called BioFX. The company developed StabilCoat Plus, a surface modification technology used in cardiovascular devices in 2003. In 2019, Surmodics received FDA approval for its SurVeil™ drug-coated balloon, offering a breakthrough treatment option for peripheral artery disease patients. With continuous innovation and dedication, Surmodics Inc strives to make impactful advancements in the medical technology industry.
Surmodics Inc is primarily present in the United States.
Surmodics Inc is a leading provider of medical device and in vitro diagnostic technologies. The company operates with a strong set of values and corporate philosophy that underpins its actions and decisions. Surmodics is committed to innovation, continuously striving to develop breakthrough solutions that positively impact patient outcomes. The company places a strong emphasis on integrity, conducting business with the highest ethical standards and fostering a culture of accountability. Surmodics also embraces collaboration, working closely with customers, partners, and internal teams to deliver the most advanced solutions. With a focus on quality, Surmodics ensures that its products meet the highest standards of reliability and performance, putting patient safety and well-being at the forefront of its operations. Overall, Surmodics Inc represents a commitment to innovation, integrity, collaboration, and quality in the medical device industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 43,86 USD per l’azione Surmodics (mediana: 43,86 USD), pari a +2,0 % rispetto all’ultimo prezzo. Il consenso si basa su 9 giudizi di analisti.
7 analisti valutano attualmente l’azione Surmodics: 0 raccomandano l’acquisto, 4 la tenuta e 3 la vendita. Per il 2026 gli analisti si aspettano per Surmodics ricavi pari a 123,01 Mio. USD e un utile per azione di -0,12 USD.
Convertita al tasso di cambio attuale, l’azione Surmodics quota 38,37 EUR (42,98 USD).
L’azione Surmodics (SRDX) è quotata su 2 borse, tra cui: NASDAQ (SRDX), Frankfurt (SU6.F).
Surmodics Inc. is a renowned manufacturer of medical devices and products used in in vitro diagnostics, medical technology, and drug delivery. The company offers a wide range of innovative solutions based on nanotechnology and surface chemistry. Its core competencies include the development and manufacturing of medical coatings that can be applied to polymers, metals, and glass. These coatings are capable of improving the performance and extending the lifespan of medical devices and products. Surmodics Inc. also specializes in the development and manufacturing of reagents and detection devices for in vitro diagnostics, offering specialized kits and assays for quick and reliable determination of clinical parameters such as blood sugar levels or inflammation indicators. In the field of medical technology, Surmodics Inc. is mainly focused on the development of minimally invasive catheters and implants. These products are equipped with special coatings that prevent the penetration of bacteria and other pathogens, thus minimizing the risk of infections. Surmodics Inc. is also a key player in the drug delivery market, offering a wide range of products based on micro and nanotechnology. These include implants that release precisely dosed active ingredients, as well as intelligent delivery systems that automatically adapt to the individual needs of the patient. Surmodics Inc. is a strong and highly innovative company known for its continuous product development and quality assurance. The company works closely with its customers to develop individual solutions that meet their specific requirements.
Il attesa fatturato di Surmodics ammonta a 123,01 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Surmodics ammonta a -1,72 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Surmodics è attualmente -356,44. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Surmodics.
Il rapporto prezzo/fatturato (P/S) di Surmodics è attualmente 4,97. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Surmodics.
Il Quality Score AlleAktien per Surmodics è 2/10.
L'ISIN di Surmodics è US8688731004. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Surmodics è 914178. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Surmodics è SRDX. Con questo simbolo di borsa vengono negoziate le azioni Surmodics in borsa.
Azione Surmodics
Gruppo di pari di Surmodics
Surmodics Ticker
Surmodics FIGI
Altre metriche e analisi di Surmodics in Deep Dive.
La nostra analisi azionaria dell'azione Surmodics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Surmodics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: